News

ProJenX receives $15M in funding to further develop prosetin for ALS

The biotechnology company ProJenX recently received $15 million in funding to advance its experimental oral treatment prosetin for amyotrophic lateral sclerosis (ALS). This Series A financing round is essentially the next round of funding after seed money was used to rapidly develop the investigational treatment. Both rounds…

Environmental pollutants in blood linked to ALS risk, survival

A person’s degree of exposure to multiple environmental pollutants — reflected by their presence in the blood — may be used to predict amyotrophic lateral sclerosis (ALS) risk and survival, according to new research. Greater exposure to these chemicals was associated with increased odds of an individual developing ALS,…

Gene activity altered in certain brain cells of people with C9-ALS

The genetic activity of certain brain cells, namely excitatory neurons and astrocytes, is altered in people with amyotrophic lateral sclerosis (ALS) caused by mutations in the C9ORF72 gene, a study reports. The data reveal the distinct molecular mechanisms that may lead to disease progression in people with such mutations, which…

Zydus launches Phase 2 trial of anti-inflammatory ZYIL1

Zydus Lifesciences has launched a Phase 2 clinical trial to evaluate the safety and effectiveness of its experimental anti-inflammatory therapy ZYIL1 in people with amyotrophic lateral sclerosis (ALS). The company announced it has received clearance for the clinical trial (NCT05981040) from India’s Central Drugs Standard Control Organization…